Back to News
Market Impact: 0.35
GMED Q3 Earnings Call Highlights Guidance Cut and 2027 Reset
Source: zacks.com
Corporate Guidance & OutlookHealthcare & BiotechCompany FundamentalsProduct Launches
Globus Medical cut its 2026 revenue outlook, citing delays in spine product launches and weak sales at Nevro. The company is shifting its focus toward new products and growth opportunities in 2027; the article provides no revised revenue figure or quantified outlook change.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
GMED-0.70
More News
- Globus Medical stock holds at Neutral as BTIG cites revenue miss
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- Paraguay’s Santiago Pena under arrest, new president Pedro Alliana sworn in